Use of LDH and autoimmune side effects to predict response to ipilimumab treatment

Immunotherapy

Volumn 8, Issue 9, 2016, Pages 1033-1044

  Dick, J ^a   Lang, N ^a   Slynko, A ^b   Kopp Schneider, A ^b   Schulz, C ^a   Dimitrakopoulou Strauss, A ^b   Enk, A H ^a   Hassel, J C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

autoimmune side effects; ipilimumab; LDH; melanoma

Indexed keywords

C REACTIVE PROTEIN; IPILIMUMAB; LACTATE DEHYDROGENASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PHARMACOLOGICAL BIOMARKER;

ADOLESCENT; ADULT; AGED; ALOPECIA AREATA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE PANCREATITIS; CANCER CHEMOTHERAPY; COLITIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSITIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN TOXICITY; SURVIVAL TIME; AUTOIMMUNE DISEASES; CELL PROLIFERATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; T LYMPHOCYTE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BIOMARKERS, PHARMACOLOGICAL; C-REACTIVE PROTEIN; CELL PROLIFERATION; CTLA-4 ANTIGEN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84981186635     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0083     Document Type: Article

References (26)

1. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
2. Ascierto PA, Simeone E, Sileni VC et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J. Transl. Med. 12, 116 (2014).
3. Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur. J. Nucl. Med. Mol. Imaging 42(3), 386-396 (2015).
4. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
5. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin. Cancer Res. 19(5), 1009-1020 (2013).
6. Kelderman S, Heemskerk B, Van Tinteren H et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol. Immunother. 63(5), 449-458 (2014).
7. Snyder A, Wolchok JD, Chan TA. Genetic basis for clinical response to CTLA-4 blockade. N. Engl. J. Med. 372(8), 783 (2015).
8. Hannani D, Vetizou M, Enot D et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 25(2), 208-224 (2015).
9. Wolchok JD, Hoos A, O'day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
10. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J. Clin. Oncol. 1(11), 710-719 (1983).
11. Ugurel S, Loquai C, Kahler K et al. A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Ann. Oncol. 26(3), 573-582 (2015).
12. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199-6206 (2009).
13. Simeone E, Gentilcore G, Giannarelli D et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol. Immunother. 63(7), 675-683 (2014).
14. Zaragoza J, Caille A, Beneton N et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. 174(1), 146-151 (2016).
15. Krajsova I, Arenberger P, Lakomy R et al. Long-term survival with ipilimumab: experience from a National Expanded Access Program for patients with melanoma. Anticancer Res. 35(11), 6303-6310 (2015).
16. Wilgenhof S, Du Four S, Vandenbroucke F et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J. Immunother. 36(3), 215-222 (2013).
17. Delyon J, Mateus C, Lefeuvre D et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann. Oncol. 24(6), 1697-1703 (2013).
18. Eigentler TK, Schlaak M, Hassel JC et al. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. J. Immunother. 37(7), 374-381 (2014).
19. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25), 6043-6053 (2005).
20. Gamba CS, Clarke CA, Keegan TH, Tao L, Swetter SM. Melanoma survival disadvantage in young, non-Hispanic white males compared with females. JAMA Dermatol. 149(8), 912-920 (2013).
21. Loquai C, Muller-Brenne T, Schadmand-Fischer S, Grabbe S. Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report. Onkologie 36(10), 578-581 (2013).
22. Sanmamed MF, Fernandez-Landazuri S, Rodriguez C et al. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clin. Chim. Acta 429 168-174 (2014).
23. Kucera R, Topolcan O, Treskova I et al. Evaluation of IL-2, IL-6, IL-8 and IL-10 in malignant melanoma diagnostics. Anticancer Res. 35(6), 3537-3541 (2015).
24. Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257), 207-211 (2015).
25. Thomas NE, Busam KJ, From L et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J. Clin. Oncol. 31(33), 4252-4259 (2013).
26. Halama N, Michel S, Kloor M et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 71(17), 5670-5677 (2011).